文献速递胸部肿瘤

人类白细胞抗原基因型与非小细胞肺癌单药免疫治疗中免疫相关不良事件发生的关联

Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy.
PubMed 文献 · Eur J Cancer · 2022-06-24

该研究对179例接受抗PD-1/PD-L1治疗的非小细胞肺癌患者进行高分辨率HLA-I分型,分析HLA-I/II纯合性、超型及等位基因与irAE的相关性。结果显示HLA-I纯合与irAE风险降低相关(RR=0.61),HLA-A03超型与irAE风险升高相关(RR=1.42),发生irAE与更好的CBR、PFS和OS相关。

要点

  • HLA-I纯合与irAE风险降低相关(RR=0.61,95%CI 0.33-0.95,P=0.035)。
  • HLA-A03超型与irAE风险升高相关(RR=1.42,95%CI 1.02-2.01,P=0.039)。
  • 发生任何irAE与改善的CBR(RR=1.48)、PFS(HR=0.45)和OS(HR=0.34)显著相关。

核心结论

  • 一个或多个HLA-I位点纯合可能作为生物标志物,预测非小细胞肺癌抗PD-1/PD-L1治疗患者不太可能发生严重irAE,但也不太可能获得临床获益。
  • HLA-I纯合患者可能从额外治疗中获益。

研究设计与样本

  • 对179例接受抗PD-1/PD-L1治疗的非小细胞肺癌患者进行高分辨率HLA-I分型。
  • 毒性数据按CTCAE v5.0收集和分级。
  • 采用14.8周界标分析以处理领先时间偏倚,研究HLA-I/II纯合性、超型及等位基因与irAE的相关性。
  • 评估irAE与临床获益率(CBR)、无进展生存期(PFS)和总生存期(OS)的关联。

主要发现

  • 一个或多个HLA-I位点纯合(而非HLA-II)与irAE风险降低相关(RR=0.61,95%CI 0.33-0.95,P=0.035),尤其是肺炎或任何3级毒性。
  • HLA-A03超型患者发生irAE的风险更高(RR=1.42,95%CI 1.02-2.01,P=0.039)。
  • 发生任何irAE与改善的CBR显著相关(RR=1.48,P<0.0001)。
  • 发生任何irAE与改善的PFS显著相关(HR=0.45,P=0.0003)。
  • 发生任何irAE与改善的OS显著相关(HR=0.34,P<0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Biomarkers that predict the risk of immune-mediated adverse events (irAEs) among patients with non-small cell lung cancer (NSCLC) may reduce morbidity and mortality associated with these treatments. METHODS: We carried out high resolution human leucocyte antigen (HLA)-I typing on 179 patients with NSCLC treated with anti-program death (PD)-1/program death ligand (PDL)-1. Toxicity data were collected and graded as per common terminology criteria for adverse event (CTCAE) v5.0. We used 14.8-week for landmark analysis to address lead-time bias to investigate the correlation between HLA-I/II zygosity, supertypes and alleles with irAE. Furthermore, we assessed the association for irAE with clinical benefit rate (CBR), progression-free survival (PFS) and overall survival (OS). RESULTS: Homozygosity at one or more HLA-I loci, but not HLA-II, was associated with a reduced risk of irAE (relative risk (RR) = 0.61, 95% CI 0.33-0.95, P = 0.035) especially pneumonitis or any grade 3 toxicity. Patients with HLA-A03 supertype had a higher risk of developing irAE (RR = 1.42, 95% CI 1.02-2.01, P = 0.039). The occurrence of any irAE was significantly associated with improved CBR (RR = 1.48, P < 0.0001), PFS (HR = 0.45, P = 0.0003) and OS (HR = 0.34, P < 0.0001). CONCLUSIONS: Homozygosity at one or more HLA-I loci may serve as biomarker to predict patients who are unlikely to experience severe irAEs among patients with NSCLC and treated with anti-PD1/PDL1, but less likely to derive clinical benefit. Patients with HLA-I homozygous might benefit from additional therapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Abed A, Law N, Calapre L, et al. Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy. Eur J Cancer. 2022. PMID: 35759816. doi:10.1016/j.ejca.2022.05.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。